<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03825874</url>
  </required_header>
  <id_info>
    <org_study_id>MIKA</org_study_id>
    <secondary_id>2017-A02372-51</secondary_id>
    <nct_id>NCT03825874</nct_id>
  </id_info>
  <brief_title>Research of the Consequences on the Digestive Tract Following the Proposed Treatments for a Urinary Infection in Children</brief_title>
  <acronym>MIKA</acronym>
  <official_title>Comparison of the Impact on Digestive Portage of Broad Spectrum Beta-Lactamase-Producing Enterobacteriaceae (E-ESBLs) of Proposed Treatments in Outbreaks of Childhood Urinary Tract Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Intercommunal Creteil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Intercommunal Creteil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The emergence of extended-spectrum beta-lactamase-producing Enterobacteriaceae (E-ESBL) is a&#xD;
      major public health problem. It leads more frequent prescription of penems with the risk of&#xD;
      emergence and spread of strains producing carbapenemases, which may be resistant to all known&#xD;
      antibiotics. A policy of savings of penems is desirable. Among the alternatives to penems,&#xD;
      amikacin is in the foreground. It remains active on the majority of E-ESBL strains. Some risk&#xD;
      factors for E-ESBL emergence are known: recent antibiotic therapy (particularly quinolones&#xD;
      and cephalosporins third generation), previous hospitalization or residence in a high endemic&#xD;
      country.&#xD;
&#xD;
      In pediatrics, E-ESBLs are primarily responsible for urinary tract infection. In France,&#xD;
      E-ESBLs represent about 10% of the strains responsible for urinary tract infections. The&#xD;
      Pathology Group Pediatric Infectious (GPIP) of the French Society of Pediatrics (SFP) and the&#xD;
      Society of Infectious Pathology French Language (SPILF) have proposed different therapeutic&#xD;
      options to treat febrile UTIs in children: amikacin intravenous; intravenous (IV) ceftriaxone&#xD;
      or intramuscular (IM); or cefixime per-os (PO).&#xD;
&#xD;
      The objective of this study is to compare the emergence of E-ESBLs in stools of children&#xD;
      after febrile UTIs treatment with amikacin IV versus ceftriaxone or cefixime.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2019</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of E-BLSE in stools</measure>
    <time_frame>day 4</time_frame>
    <description>ano-rectal swab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Type of E-BLSE strain in stools</measure>
    <time_frame>day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of enzymatic resistance of E-BLSE strain in stools</measure>
    <time_frame>4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fever</measure>
    <time_frame>4 days</time_frame>
    <description>Time of apyrexia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects due to antibiotic therapy</measure>
    <time_frame>at 1.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of relapse of urinary tract infection</measure>
    <time_frame>1.5 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Urinary Tract Infections</condition>
  <condition>Urinary Tract Infections in Children</condition>
  <arm_group>
    <arm_group_label>amikacin IV</arm_group_label>
    <description>Febrile urinary tract infection treated with amikacin IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other antibiotics</arm_group_label>
    <description>Febrile urinary tract infection treated with other antibiotic, according to the recommendations: ceftriaxone or cefixime</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Amikacin</intervention_name>
    <description>A first anorectal swab will be performed before starting any antibiotic treatment Three to four days after the start of antibiotic treatment, patients will be seen again and a new anorectal swab will be performed.</description>
    <arm_group_label>amikacin IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>usual antibiotic treatment</intervention_name>
    <description>A first anorectal swab will be performed before starting any antibiotic treatment Three to four days after the start of antibiotic treatment, patients will be seen again and a new anorectal swab will be performed.</description>
    <arm_group_label>Other antibiotics</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      anorectal swab&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Child from 3 months to 3 years treated for febrile urinary tract infection&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infant and child (age ≥ 3 months and &lt;3 years)&#xD;
&#xD;
          -  Patient treated for febrile urinary tract infection as monotherapy with amikacin IV,&#xD;
             ceftriaxone (IV or IM) or cefixime PO *&#xD;
&#xD;
          -  Whose parents read and understood the newsletter and whose express consent was&#xD;
             collected&#xD;
&#xD;
          -  Patient affiliated to a social security scheme (Social Security or Universal Medical&#xD;
             Coverage)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Child treated with more than one antibiotic (eg treatment with dual therapy&#xD;
             ceftriaxone / cefotaxime and aminoglycoside)&#xD;
&#xD;
          -  Antibiotherapy in progress or discontinued in the previous 7 days&#xD;
&#xD;
          -  Hospitalized child&#xD;
&#xD;
          -  Refusal of one of the parents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>3 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Fouad MADHI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHI Créteil</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fouad Madhi, MD</last_name>
    <phone>+33157025422</phone>
    <email>fouad.madhi@chicreteil.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Antoine Beclère Hospital</name>
      <address>
        <city>Clamart</city>
        <state>Ile-de France</state>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincent Gadjos</last_name>
      <email>vincent.gajdos@abc.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jean Verdier Hospital</name>
      <address>
        <city>Bondy</city>
        <state>Ile-de-France</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélien Galerne</last_name>
      <email>aurelien.galerne@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>André Mignot Hospital</name>
      <address>
        <city>Le Chesnay</city>
        <state>Ile-de-France</state>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie-Aliette Dommergues</last_name>
      <email>madommergues@ch-versailles.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr Benali</name>
      <address>
        <city>Charenton-le-Pont</city>
        <zip>94220</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hadj Benali</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr Coicadan</name>
      <address>
        <city>Chennevières-sur-Marne</city>
        <zip>94430</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucette Coicadan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr Corrard</name>
      <address>
        <city>Combs-la-Ville</city>
        <zip>77380</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Corrard</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr Thollot</name>
      <address>
        <city>Essey-lès-Nancy</city>
        <zip>54270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck Thollot</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Le Kremlin-Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Irina Craiu</last_name>
      <email>craiu@voila.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>157 Avenue du Général Leclerc</name>
      <address>
        <city>Maisons-Alfort</city>
        <zip>94700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Annie ELBEZ</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Meaux</name>
      <address>
        <city>Meaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier Vignaud</last_name>
      <email>o-vignaud@ch-meaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr Deberdt</name>
      <address>
        <city>Nogent-sur-Marne</city>
        <zip>94130</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice Deberdt</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr Wollner</name>
      <address>
        <city>Nogent-sur-Marne</city>
        <zip>94130</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Wollner</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr Romain</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Romain</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr Turberg-Romain</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Turberg-Romain</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr Michot</name>
      <address>
        <city>Paris</city>
        <zip>75016</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Sylvestre Michot</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Robert-Debré</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexis Rybak</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr Cohen</name>
      <address>
        <city>Saint-Maur-des-Fossés</city>
        <zip>94100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Cohen</last_name>
    </contact>
    <investigator>
      <last_name>Mohammed Benani</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nadia D'Ovidio</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Koskas</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aurélie SELLAM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr Werner</name>
      <address>
        <city>Villeneuve-lès-Avignon</city>
        <zip>30400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Werner</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHI Villeneuve-Saint-Georges</name>
      <address>
        <city>Villeneuve-Saint-Georges</city>
        <zip>94195</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélie GARRAFFO</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>13 Villa Beauséjour</name>
      <address>
        <city>Vincennes</city>
        <zip>94300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe BATARD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 8, 2018</study_first_submitted>
  <study_first_submitted_qc>January 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2019</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Amikacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

